A PHASE 3 OPEN LABEL CONTINUATION PROTOCOL OF A FIXED DOSE COMBINATION OF AROXYBUTYNIN AND ATOMOXETINE (AD109) IN OBSTRUCTIVE SLEEP APNEA
- Registry ID
- APC-APN-306
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- APNIMED, INC
- Start date
- 2024-12-09
- Last update
- 2024-06-14
Conditions
Related clinical trials
- A MASTER PROTOCOL FOR PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE WEEKLY ELORALINTIDE IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA, AND OBESITY OR OVERWEIGHT (ENLIGHTEN-3)
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MARIDEBART CAFRAGLUTIDE IN ADULT PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA ON POSITIVE AIRWAY PRESSURE THERAPY AND LIVING WITH OVERWEIGHT OR OBESITY (MARITIME-OSA-1)
- DEXAMETHASONE AS A NOVEL TREATMENT FOR OBSTRUCTIVE SLEEP APNEA IN CHILDREN
- SOLRIAMFETOL'S EFFECT ON COGNITIVE HEALTH IN APNEA PARTICIPANTS DURING A RANDOMIZED PLACEBO-CONTROLLED STUDY (SHARP): A 5-WEEK DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, CROSSOVER, MULTICENTER STUDY OF SOLRIAMFETOL IN IMPROVING COGNITIVE FUNCTION
- A LONG-TERM, OPEN-LABEL, SAFETY AND MAINTENANCE OF EFFICACY STUDY OF JZP-110 [(R)-2-AMINO-3-PHENYLPROPYLCARBAMATE HYDROCHLORIDE] IN THE TREATMENT OF EXCESSIVE SLEEPINESS IN SUBJECTS WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA).
View on source registry